74 results on '"Makishima H"'
Search Results
2. Clinical Outcomes of Carbon-Ion Radiotherapy for Large-Sized (≥4cm) Hepatocellular Carcinoma
- Author
-
Wakatsuki, M., primary, Makishima, H., additional, Mori, Y., additional, Kaneko, T., additional, Yasuda, S., additional, Okada, N., additional, Nakajima, M., additional, Murata, K., additional, Okonogi, N., additional, Aoki, S., additional, Ishikawa, H., additional, and Yamada, S., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Development of a Machine Learning Model to Evaluate Changes during Radiotherapy in Cervical Cancer Tumor Cells
- Author
-
Goto, M., primary, Futamura, Y., additional, Makishima, H., additional, Sakamoto, N., additional, Iijima, T., additional, Tamaki, Y., additional, Sakurai, T., additional, and Sakurai, H., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Proton Beam Therapy for HCC Exceeding up-to-Seven Criteria
- Author
-
Makishima, H., primary, Iizumi, T., additional, Saito, T., additional, Numajiri, H., additional, Nakai, K., additional, Mizumoto, M., additional, Okumura, T., additional, and Sakurai, H., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Outcome of Proton Beam Therapy for Primary Hepatocellular Carcinoma with “Unfavorable” Macroscopic Classification
- Author
-
Niitsu, H., primary, Makishima, H., additional, Iizumi, T., additional, Saito, T., additional, Numajiri, H., additional, Nakai, K., additional, Mizumoto, M., additional, Okumura, T., additional, and Sakurai, H., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA
- Author
-
Okuda, R., primary, Ochi, Y., additional, Saiki, R., additional, Chonabayashi, K., additional, Hiramoto, N., additional, Sanada, M., additional, Handa, H., additional, Kasahara, S., additional, Sato, S., additional, Kanemura, N., additional, Kitano, T., additional, Watanabe, M., additional, Kern, W., additional, Creignou, M., additional, Shiraishi, Y., additional, Usuki, K., additional, Imashuku, S., additional, Hellstrom-Lindberg, E., additional, Haferlach, T., additional, Chiba, S., additional, Sezaki, N., additional, Shih, L.-Y., additional, Miyazaki, Y., additional, Yoshida, Y., additional, Ishikawa, T., additional, Ohyashiki, K., additional, Atsuta, Y., additional, Shiozawa, Y., additional, Miyano, S., additional, Makishima, H., additional, Nannya, Y., additional, and Ogawa, S., additional
- Published
- 2023
- Full Text
- View/download PDF
7. POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS
- Author
-
Nannya, Y., primary, Tobiasson, M., additional, Sato, S., additional, Bernard, E., additional, Ohtake, S., additional, Takeda, J., additional, Creignou, M., additional, Kusakabe, M., additional, Shibata, Y., additional, Nakamura, N., additional, Watanabe, M., additional, Hiramoto, N., additional, Shiozawa, Y., additional, Shiraishi, Y., additional, Tanaka, H., additional, Yoshida, K., additional, Kakicuchi, N., additional, Makishima, H., additional, Nakagawa, M., additional, Usuki, K., additional, Imada, K., additional, Handa, H., additional, Taguchi, M., additional, Kiguchi, T., additional, Ohyashiki, K., additional, Ishikawa, T., additional, Takaori, A., additional, Tsurumi, H., additional, Kasahara, S., additional, Chiba, S., additional, Naoe, T., additional, Miyano, S., additional, Papaemmanuil, E., additional, Miyazaki, Y., additional, Hellstrom-Lindberg, E., additional, and Ogawa, S., additional
- Published
- 2023
- Full Text
- View/download PDF
8. CTX-712, A NOVEL SPLICING INHIBITOR TARGETING MYELOID NEOPLASMS
- Author
-
Yoda, A., primary, Morishita, D., additional, Ochi, Y., additional, Mizutani, A., additional, Mori, T., additional, Takeda, J., additional, Tozaki, H., additional, Satoh, Y., additional, Makishima, H., additional, Nakagawa, M., additional, Nannya, Y., additional, and Ogawa, S., additional
- Published
- 2023
- Full Text
- View/download PDF
9. DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING
- Author
-
Nakagawa, M., primary, Inagaki, R., additional, Kuroda, Y., additional, Nannya, Y., additional, Zhao, L., additional, Ochi, Y., additional, Motomura, M., additional, Takeda, J., additional, Qi, X., additional, Okazaki, K., additional, Yoda, A., additional, Kon, A., additional, Kakiuchi, N., additional, Makishima, H., additional, Matsuda, S., additional, and Ogawa, S., additional
- Published
- 2023
- Full Text
- View/download PDF
10. GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY
- Author
-
Makishima, H., primary
- Published
- 2023
- Full Text
- View/download PDF
11. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
- Author
-
Makishima, H., Saiki, R., Nannya, Y., Korotev, S., Gurnari, C., Takeda, J., Momozawa, Y., Best, S., Krishnamurthy, P., Yoshizato, T., Atsuta, Y., Shiozawa, Y., Iijima-Yamashita, Y., Yoshida, K., Shiraishi, Y., Nagata, Y., Kakiuchi, N., Onizuka, M., Chiba, K., Tanaka, H., Kon, A., Ochi, Y., Nakagawa, M.M., Okuda, R., Mori, T., Yoda, A., Itonaga, H., Miyazaki, Y., Sanada, M., Ishikawa, T., Chiba, S., Tsurumi, H., Kasahara, S., Müller-Tidow, C., Takaori-Kondo, A., Ohyashiki, K., Kiguchi, T., Matsuda, F., Jansen, J.H., Polprasert, C., Blombery, P., Kamatani, Y., Miyano, S., Malcovati, L., Haferlach, T, Kubo, M., Cazzola, M., Kulasekararaj, A.G., Godley, L.A., Maciejewski, J.P., Ogawa, S., Makishima, H., Saiki, R., Nannya, Y., Korotev, S., Gurnari, C., Takeda, J., Momozawa, Y., Best, S., Krishnamurthy, P., Yoshizato, T., Atsuta, Y., Shiozawa, Y., Iijima-Yamashita, Y., Yoshida, K., Shiraishi, Y., Nagata, Y., Kakiuchi, N., Onizuka, M., Chiba, K., Tanaka, H., Kon, A., Ochi, Y., Nakagawa, M.M., Okuda, R., Mori, T., Yoda, A., Itonaga, H., Miyazaki, Y., Sanada, M., Ishikawa, T., Chiba, S., Tsurumi, H., Kasahara, S., Müller-Tidow, C., Takaori-Kondo, A., Ohyashiki, K., Kiguchi, T., Matsuda, F., Jansen, J.H., Polprasert, C., Blombery, P., Kamatani, Y., Miyano, S., Malcovati, L., Haferlach, T, Kubo, M., Cazzola, M., Kulasekararaj, A.G., Godley, L.A., Maciejewski, J.P., and Ogawa, S.
- Abstract
Item does not contain fulltext, Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization of DDX41-mutated MNs, enrolling a total of 346 patients with DDX41 pathogenic/likely-pathogenic (P/LP) germ line variants and/or somatic mutations from 9082 MN patients, together with 525 first-degree relatives of DDX41-mutated and wild-type (WT) patients. P/LP DDX41 germ line variants explained ∼80% of known germ line predisposition to MNs in adults. These risk variants were 10-fold more enriched in Japanese MN cases (n = 4461) compared with the general population of Japan (n = 20 238). This enrichment of DDX41 risk alleles was much more prominent in male than female (20.7 vs 5.0). P/LP DDX41 variants conferred a large risk of developing MNs, which was negligible until 40 years of age but rapidly increased to 49% by 90 years of age. Patients with myelodysplastic syndromes (MDS) along with a DDX41-mutation rapidly progressed to acute myeloid leukemia (AML), which was however, confined to those having truncating variants. Comutation patterns at diagnosis and at progression to AML were substantially different between DDX41-mutated and WT cases, in which none of the comutations affected clinical outcomes. Even TP53 mutations made no exceptions and their dismal effect, including multihit allelic status, on survival was almost completely mitigated by the presence of DDX41 mutations. Finally, outcomes were not affected by the conventional risk stratifications including the revised/molecular International Prognostic Scoring System. Our findings establish that MDS with DDX41-mutation defines a unique subtype of MNs that is distinct from other MNs.
- Published
- 2023
12. P037 - Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA
- Author
-
Okuda, R., Ochi, Y., Saiki, R., Chonabayashi, K., Hiramoto, N., Sanada, M., Handa, H., Kasahara, S., Sato, S., Kanemura, N., Kitano, T., Watanabe, M., Kern, W., Creignou, M., Shiraishi, Y., Usuki, K., Imashuku, S., Hellstrom-Lindberg, E., Haferlach, T., Chiba, S., Sezaki, N., Shih, L.-Y., Miyazaki, Y., Yoshida, Y., Ishikawa, T., Ohyashiki, K., Atsuta, Y., Shiozawa, Y., Miyano, S., Makishima, H., Nannya, Y., and Ogawa, S.
- Published
- 2023
- Full Text
- View/download PDF
13. O11 - POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS
- Author
-
Nannya, Y., Tobiasson, M., Sato, S., Bernard, E., Ohtake, S., Takeda, J., Creignou, M., Kusakabe, M., Shibata, Y., Nakamura, N., Watanabe, M., Hiramoto, N., Shiozawa, Y., Shiraishi, Y., Tanaka, H., Yoshida, K., Kakicuchi, N., Makishima, H., Nakagawa, M., Usuki, K., Imada, K., Handa, H., Taguchi, M., Kiguchi, T., Ohyashiki, K., Ishikawa, T., Takaori, A., Tsurumi, H., Kasahara, S., Chiba, S., Naoe, T., Miyano, S., Papaemmanuil, E., Miyazaki, Y., Hellstrom-Lindberg, E., and Ogawa, S.
- Published
- 2023
- Full Text
- View/download PDF
14. O04 - DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING
- Author
-
Nakagawa, M., Inagaki, R., Kuroda, Y., Nannya, Y., Zhao, L., Ochi, Y., Motomura, M., Takeda, J., Qi, X., Okazaki, K., Yoda, A., Kon, A., Kakiuchi, N., Makishima, H., Matsuda, S., and Ogawa, S.
- Published
- 2023
- Full Text
- View/download PDF
15. O09 - CTX-712, A NOVEL SPLICING INHIBITOR TARGETING MYELOID NEOPLASMS
- Author
-
Yoda, A., Morishita, D., Ochi, Y., Mizutani, A., Mori, T., Takeda, J., Tozaki, H., Satoh, Y., Makishima, H., Nakagawa, M., Nannya, Y., and Ogawa, S.
- Published
- 2023
- Full Text
- View/download PDF
16. IS17 - GERMLINE DDX41 MUTATIONS : CLINICAL IMPACT & ETHNIC DIVERSITY
- Author
-
Makishima, H.
- Published
- 2023
- Full Text
- View/download PDF
17. Comparison of External Beam Radiation Modalities (Photon vs. Proton vs. Carbon Ion) in the Treatment of Hepatocellular Carcinoma: A Network Metanalysis
- Author
-
Nganga, D., Yariv, O., Escorcia, F.E., Tan, X., Makishima, H., Apisarnthanarax, S., Reig, M., Moon, A.M., and Yanagihara, T.
- Published
- 2024
- Full Text
- View/download PDF
18. P737: FUNCTIONAL ROLES OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES
- Author
-
Kon, A., primary, Nakagawa, M., additional, Kataoka, K., additional, Makishima, H., additional, Nakayama, M., additional, Koseki, H., additional, Nannya, Y., additional, and Ogawa, S., additional
- Published
- 2022
- Full Text
- View/download PDF
19. P741: DDX41 MUTATIONS DEFINE A UNIQUE SUBTYPE OF MYELOID NEOPLASMS.
- Author
-
Makishima, H., primary, Saiki, R., additional, Nannya, Y., additional, Korotev, S., additional, Gurnari, C., additional, Takeda, J., additional, Momozawa, Y., additional, Best, S., additional, Krishnamurthy, P., additional, Yoshizato, T., additional, Atsuta, Y., additional, Shiozawa, Y., additional, Iijima-Yamashita, Y., additional, Yoshida, K., additional, Shiraishi, Y., additional, Nagata, Y., additional, Kakiuchi, N., additional, Onizuka, M., additional, Chiba, K., additional, Tanaka, H., additional, Kon, A., additional, Ochi, Y., additional, Nakagawa, M., additional, Okuda, R., additional, Mori, T., additional, Itonaga, H., additional, Miyazaki, Y., additional, Sanada, M., additional, Tsurumi, H., additional, Kasahara, S., additional, Müller-Tidow, C., additional, Takaori-Kondo, A., additional, Ohyashiki, K., additional, Kiguchi, T., additional, Matsuda, F., additional, Jansen, J., additional, Polprasert, C., additional, Miyano, S., additional, Malcovati, L., additional, Haferlach, T., additional, Kubo, M., additional, Cazzola, M., additional, Kulasekararaj, A., additional, Godley, L., additional, Maciejewski, J., additional, and Ogawa, S., additional
- Published
- 2022
- Full Text
- View/download PDF
20. P466: AMPLIFIED EPOR/JAK2 GENES DEFINE A UNIQUE SUBTYPE OF ACUTE ERYTHROID LEUKEMIA
- Author
-
Takeda, J., primary, Yoshida, K., additional, Nakagawa, M., additional, Nannya, Y., additional, Yoda, A., additional, Saiki, R., additional, Ochi, Y., additional, Zhao, L., additional, Okuda, R., additional, Qi, X., additional, Mori, T., additional, Kon, A., additional, Chiba, K., additional, Tanaka, H., additional, Shiraishi, Y., additional, Kuo, M.-C., additional, Kerr, C., additional, Nagata, Y., additional, Morishita, D., additional, Hiramoto, N., additional, Hangaishi, A., additional, Nakazawa, H., additional, Ishiyama, K., additional, Miyano, S., additional, Chiba, S., additional, Miyazaki, Y., additional, Kitano, T., additional, Usuki, K., additional, Sezaki, N., additional, Tsurumi, H., additional, Miyawaki, S., additional, Maciejewski, J., additional, Ishikawa, T., additional, Ohyashiki, K., additional, Ganser, A., additional, Heuser, M., additional, Thol, F., additional, Shih, L.-Y., additional, Takaori−Kondo, A., additional, Makishima, H., additional, and Ogawa, S., additional
- Published
- 2022
- Full Text
- View/download PDF
21. P744: UNBALANCED TRANSLOCATION DER(1;7)(Q10;P10) AS A DISTINCT SUBTYPE IN MYELODYSPLASTIC SYNDROMES
- Author
-
Okuda, R., primary, Ochi, Y., additional, Chonabayashi, K., additional, Hiramoto, N., additional, Sanada, M., additional, Handa, H., additional, Kasahara, S., additional, Sato, S., additional, Kanemura, N., additional, Kitano, T., additional, Watanabe, M., additional, Kern, W., additional, Creignou, M., additional, Shiraishi, Y., additional, Usuki, K., additional, Imashuku, S., additional, Hellstrom-Lindberg, E., additional, Haferlach, T., additional, Chiba, S., additional, Sezaki, N., additional, Shih, L.-Y., additional, Miyazaki, Y., additional, Yoshida, Y., additional, Ishikawa, T., additional, Ohyashiki, K., additional, Atsuta, Y., additional, Shiozawa, Y., additional, Miyano, S., additional, Makishima, H., additional, Nannya, Y., additional, and Ogawa, S., additional
- Published
- 2022
- Full Text
- View/download PDF
22. PO-1285 Clinical impact of carbon ion radiotherapy for hepatocellular carcinoma with Child-Pugh B cirrhosis
- Author
-
Hiroshima, Y., primary, Wakatsuki, M., additional, Kaneko, T., additional, Makishima, H., additional, Ishikawa, H., additional, and Tsuji, H., additional
- Published
- 2022
- Full Text
- View/download PDF
23. PO-1532 Long-term outcomes of proton beam therapy for elderly patients with prostate cancer
- Author
-
lizumi, T., Sawada, T., Goto, M., Li, Y., Sumiya, T., Baba, K., Murakami, M., Ishida, T., Hiroshima, Y., Nakamura, M., Sekino, Y., Saito, T., Takizawa, D., Makishima, H., Numajiri, H., Mizumoto, M., Nakai, K., Ishikawa, H., and Sakurai, H.
- Published
- 2023
- Full Text
- View/download PDF
24. Publisher Correction: Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance.
- Author
-
Wang QS, Hasegawa T, Namkoong H, Saiki R, Edahiro R, Sonehara K, Tanaka H, Azekawa S, Chubachi S, Takahashi Y, Sakaue S, Namba S, Yamamoto K, Shiraishi Y, Chiba K, Tanaka H, Makishima H, Nannya Y, Zhang Z, Tsujikawa R, Koike R, Takano T, Ishii M, Kimura A, Inoue F, Kanai T, Fukunaga K, Ogawa S, Imoto S, Miyano S, and Okada Y
- Published
- 2024
- Full Text
- View/download PDF
25. Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance.
- Author
-
Wang QS, Hasegawa T, Namkoong H, Saiki R, Edahiro R, Sonehara K, Tanaka H, Azekawa S, Chubachi S, Takahashi Y, Sakaue S, Namba S, Yamamoto K, Shiraishi Y, Chiba K, Tanaka H, Makishima H, Nannya Y, Zhang Z, Tsujikawa R, Koike R, Takano T, Ishii M, Kimura A, Inoue F, Kanai T, Fukunaga K, Ogawa S, Imoto S, Miyano S, and Okada Y
- Abstract
Studying the genetic regulation of protein expression (through protein quantitative trait loci (pQTLs)) offers a deeper understanding of regulatory variants uncharacterized by mRNA expression regulation (expression QTLs (eQTLs)) studies. Here we report cis-eQTL and cis-pQTL statistical fine-mapping from 1,405 genotyped samples with blood mRNA and 2,932 plasma samples of protein expression, as part of the Japan COVID-19 Task Force (JCTF). Fine-mapped eQTLs (n = 3,464) were enriched for 932 variants validated with a massively parallel reporter assay. Fine-mapped pQTLs (n = 582) were enriched for missense variations on structured and extracellular domains, although the possibility of epitope-binding artifacts remains. Trans-eQTL and trans-pQTL analysis highlighted associations of class I HLA allele variation with KIR genes. We contrast the multi-tissue origin of plasma protein with blood mRNA, contributing to the limited colocalization level, distinct regulatory mechanisms and trait relevance of eQTLs and pQTLs. We report a negative correlation between ABO mRNA and protein expression because of linkage disequilibrium between distinct nearby eQTLs and pQTLs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Genetic profiles and clinical features in subcutaneous panniculitis-like T-cell lymphomas.
- Author
-
Okamura Y, Makishima K, Suehara Y, Suma S, Abe Y, Matsuoka R, Sakamoto T, Hattori K, Yokoyama Y, Kato T, Nanmoku T, Iwasaki T, Nishiyama K, Kato K, Takeuchi Y, Makishima H, Nakamura N, Chiba S, and Sakata-Yanagimoto M
- Abstract
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare peripheral T-cell lymphoma characterized by cutaneous lesions and immunologic manifestations. The five-year survival rate of SPTCL has been reported to be over 80%, indicating a favorable prognosis. Recent studies have uncovered recurrent germline variants in HAVCR2, encoding an immunomodulator. In this study, we integrated whole-exome sequencing data from 60 samples collected from 36 SPTCL patients, encompassing six patients of our cohort and 30 patients of publicly available data. We identified 138 somatic mutations in skin tumors of 24 patients and HAVCR2 germline mutations in 23 of 29 patients. HAVCR2 p.Tyr82Cys mutations were identified in four of six Japanese patients. During the clinical courses of four patients, cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone were administered to all patients, but it resulted in incomplete responses in all four patients. However, disease conditions of all patients remained stable with additional treatment, including autologous peripheral blood stem cell transplantation. Over a 7.5-year median follow-up, one patient developed autoimmune-related diseases, while one developed other hematological malignancy, resulting in death. To our knowledge, this is the first report of recurrent HAVCR2 germline mutations in Japanese patients, suggesting the necessity for long-term follow-up., (© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2024
- Full Text
- View/download PDF
27. Proton Beam Therapy for Treating Patients with Hepatocellular Carcinoma with Major Portal Vein Tumor Invasion: A Single Center Retrospective Study.
- Author
-
Ishida T, Mizumoto M, Saito T, Okumura T, Miura K, Makishima H, Iizumi T, Numajiri H, Baba K, Murakami M, Nakamura M, Nakai K, and Sakurai H
- Abstract
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) has a poor prognosis and is generally not indicated for surgery. Proton beam therapy (PBT) may offer an alternative treatment. In this study, long-term outcomes were examined in 116 patients (median age 66 years, 100 males) with HCC with advanced PVTT (Vp3 or Vp4) who received PBT from April 2008 to March 2018. Of these patients, 63 received PBT as definitive treatment and 53 as palliative treatment. The representative dose was 72.6 Gy (RBE) in 22 fractions. Eight patients died in follow-up, including 72 due to tumor progression. The 5-year overall survival (OS) rate was 18.0% (95% CI 9.8-26.2%) and the 5-year local control (LC) rate was 86.1% (74.9-97.3%). In multivariate analyses, performance status and treatment strategy were significantly associated with OS. The median follow-up period for survivors with definitive treatment was 33.5 (2-129) months, and the 5-year OS rate was 25.1% (12.9-37.3%) in these cases. The median survival time after definitive irradiation was >20 months. The 5-year OS rate was 9.1% (0-19.7%) for palliative irradiation. These results compare favorably with those of other therapies and suggest that PBT is a useful option for cases of HCC with advanced PVTT that cannot undergo surgery, with an expected survival benefit and good local control. Determining the optimal indication for this treatment is a future challenge.
- Published
- 2024
- Full Text
- View/download PDF
28. Late Changes in Renal Volume and Function after Proton Beam Therapy in Pediatric and Adult Patients: Children Show Significant Renal Atrophy but Deterioration of Renal Function Is Minimal in the Long-Term in Both Groups.
- Author
-
Li Y, Mizumoto M, Nitta H, Fukushima H, Suzuki R, Hosaka S, Yamaki Y, Murakami M, Baba K, Nakamura M, Ishida T, Makishima H, Iizumi T, Saito T, Numajiri H, Nakai K, Kamizawa S, Kawano C, Oshiro Y, and Sakurai H
- Abstract
To compare late renal effects in pediatric and adult patients with malignancies after PBT involving part of the kidney. A retrospective study was conducted to assess changes in renal volume and function in 24 patients, including 12 children (1-14 years old) and 12 adults (51-80 years old). Kidney volumes were measured from CT or MRI images during follow-up. Dose-volume histograms were calculated using a treatment planning system. In children, the median volume changes for the irradiated and control kidneys were -5.58 (-94.95 to +4.79) and +14.92 (-19.45 to +53.89) mL, respectively, with a relative volume change of -28.38 (-119.45 to -3.87) mL for the irradiated kidneys. For adults, these volume changes were -22.43 (-68.7 to -3.48) and -21.56 (-57.26 to -0.16) mL, respectively, with a relative volume change of -5.83 (-28.85 to +30.92) mL. Control kidneys in children exhibited a marked increase in size, while those in adults showed slight volumetric loss. The percentage of irradiated volume receiving 10 Gy (RBE) (V10) and 20 Gy (RBE) (V20) were significantly negatively associated with the relative volume change per year, especially in children. The CKD stage based on eGFR for all patients ranged from 1 to 3 and no cases with severe renal dysfunction were found before or after PBT. Late effects on the kidneys after PBT vary among age groups. Children are more susceptible than adults to significant renal atrophy after PBT. V10 and V20 might serve as predictors of the degree of renal atrophy after PBT, especially in children. PBT has a minimal impact on deterioration of renal function in both children and adults.
- Published
- 2024
- Full Text
- View/download PDF
29. Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study.
- Author
-
Kaneko T, Makishima H, Wakatsuki M, Hiroshima Y, Matsui T, Yasuda S, Okada NN, Nemoto K, Tsuji H, Yamada S, and Miyazaki M
- Subjects
- Humans, Middle Aged, Aged, Aged, 80 and over, Retrospective Studies, Neoplasm Invasiveness, Neoplastic Processes, Neoplasm Recurrence, Local pathology, Carbon, Prognosis, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology
- Abstract
Background: Macroscopic vascular invasion (MVI) significantly impacts survival in patients with hepatocellular carcinoma (HCC), warranting systemic therapy over locoregional therapy. Despite novel approaches, HCC with MVI has a poor prognosis compared to early-to intermediate-stage HCC. This study aimed to evaluate the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for HCC characterized by MVI., Methods: This retrospective cohort study evaluated HCC patients with MVI treated using C-ion RT with a dose of 45.0-48.0 Gy/2 fractions or 52.8-60.0 Gy/4 fractions between 1995 and 2020 at our institution in Japan. We analyzed the prognostic factors and rates of local recurrence, survival, and adverse events. The local recurrence rate was determined using the cumulative incidence function, with death as a competing event. Survival rates were determined using the Kaplan-Meier method. The log-rank test for univariate analysis and the Cox proportional hazards model for multivariate analysis were used to compare subgroups., Results: In total, 76 patients with a median age of 71 years (range, 45-86 years) were evaluated. Among them, 68 had Child-Pugh grade A while eight had grade B disease. In 17 patients, the vascular tumor thrombus reached the inferior vena cava or main trunk of the portal vein. Over a median follow-up period of 27.9 months (range, 1.5-180.4 months), the 2-year overall survival, progression-free survival, and local recurrence rates were 70.0% (95% confidence interval [CI]: 57.7-79.4%), 32.7% (95% CI: 22.0-43.8%), and 8.9% (95% CI: 1.7-23.5%), respectively. A naïve tumor and a single lesion were significant prognostic factors for overall survival in the univariate analysis. Albumin-bilirubin grade 1 and a single lesion were independent prognostic factors in the multivariate analysis. Overall, four patients (5%) experienced grade 3 late adverse events, with no observed grade 4 or 5 acute or late adverse events., Conclusions: C-ion RT for HCC with MVI showed favorable local control and survival benefits with minimal toxicity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus.
- Author
-
Yanagihara TK, Tepper JE, Moon AM, Barry A, Molla M, Seong J, Torres F, Apisarnthanarax S, Buckstein M, Cardenes H, Chang DT, Feng M, Guha C, Hallemeier CL, Hawkins MA, Hoyer M, Iwata H, Jabbour SK, Kachnic L, Kharofa J, Kim TH, Kirichenko A, Koay EJ, Makishima H, Mases J, Meyer JJ, Munoz-Schuffenegger P, Owen D, Park HC, Saez J, Sanford NN, Scorsetti M, Smith GL, Wo JY, Yoon SM, Lawrence TS, Reig M, and Dawson LA
- Subjects
- Humans, Consensus, Ambulatory Care Facilities, Carbon, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy
- Abstract
Purpose: External beam radiation therapy (EBRT) is a highly effective treatment in select patients with hepatocellular carcinoma (HCC). However, the Barcelona Clinic Liver Cancer system does not recommend the use of EBRT in HCC due to a lack of sufficient evidence and intends to perform an individual patient level meta-analysis of ablative EBRT in this population. However, there are many types of EBRT described in the literature with no formal definition of what constitutes "ablative." Thus, we convened a group of international experts to provide consensus on the parameters that define ablative EBRT in HCC., Methods and Materials: Fundamental parameters related to dose, fractionation, radiobiology, target identification, and delivery technique were identified by a steering committee to generate 7 Key Criteria (KC) that would define ablative EBRT for HCC. Using a modified Delphi (mDelphi) method, experts in the use of EBRT in the treatment of HCC were surveyed. Respondents were given 30 days to respond in round 1 of the mDelphi and 14 days to respond in round 2. A threshold of ≥70% was used to define consensus for answers to each KC., Results: Of 40 invitations extended, 35 (88%) returned responses. In the first round, 3 of 7 KC reached consensus. In the second round, 100% returned responses and consensus was reached in 3 of the remaining 4 KC. The distribution of answers for one KC, which queried the a/b ratio of HCC, was such that consensus was not achieved. Based on this analysis, ablative EBRT for HCC was defined as a BED10 ≥80 Gy with daily imaging and multiphasic contrast used for target delineation. Treatment breaks (eg, for adaptive EBRT) are allowed, but the total treatment time should be ≤6 weeks. Equivalent dose when treating with protons should use a conversion factor of 1.1, but there is no single conversion factor for carbon ions., Conclusions: Using a mDelphi method assessing expert opinion, we provide the first consensus definition of ablative EBRT for HCC. Empirical data are required to define the a/b of HCC., Competing Interests: Disclosures Ted K. Yanagihara reports grants or contracts from the Radiation Oncology Institute and Lineberger Comprehensive Cancer Center; serving as an expert independent reviewer for the North Carolina Medical Board; and serving as an American Board of Radiology Maintenance of Certification online longitudinal assessment senior reviewer. Andrew M. Moon reports grants or contracts from the American Association for the Study of Liver Diseases, the American College of Gastroenterology, and the National Institutes of Health; consulting feeds from Target RWE; and serving on the American Association for the Study of Liver Diseases Practice Guidelines Committee. Aisling Barry reports honoria from Eisai. Ferran Torres reports grants or contracts from the Hospital Clinic Barcelona (IDIBAPS); consulting fees from Universal DX; and participation in the data safety monitoring board/advisory board of the Hospital Clinic Barcelona with partial support from Bayer. Daniel T. Chang reports grants or contracts from RefleXion Medical, ViewRay, Inc, Varian Medical Systems; honoraria for presentation from Varian Medical Systems; support for attending meetings and travel from Varian Medical Systems; and participation on data safety monitoring board for the SMART trial for ViewRay. Chandan Guha reports grants or contracts from the NIH, Janssen and Celldex; consulting fees from Janssen; participation in the data safety monitoring board or advisory board of the Focused Ultrasound Foundation; and is a founder of BioConvergent Health. Morten Hoyer reports honoraria from Novo Nordisk. Lisa Kachnic reports receiving grants or contracts from Varian Medical Systems; serving as an editor for UpToDate; participation on the data safety monitoring committee for Beta Innovations; and is a board member of the Radiation Therapy Oncology Group. Eugene J. Koay reports funding from the Department of Defense and National Institutes of Health; grants or contracts from Philips Healthcare, GE Healthcare, Stand up to Cancer, Project Purple, Elekta, Department of Defense; royalties from Taylor and Francis, LLC; consulting fees from RenovoRx, AstraZeneca, Augmenix, and Kallisio; honoraria for lectures from Apollo Cancer hospitals in Chnnai India, Bayer Healthcare, Philips Healthcare, and Aptitude Health; a patent pending for 3-dimensional printed oral stents; serving on the scientific medical advisory board of the International Cholangiocarcinoma Research Network; and stock ownership of Quantum Aurea Capital. Joel Mases reports grants or contracts from Boston Scientific and royalties or licenses from Springer and UpToDate. Pablo Munoz-Schuffenegger reports grants or contracts from the National Fund for Scientific and Technological Development, National Commission for Scientific and Technological Research, Government of Chile; honoraria for lectures from Bayer and Roche Pharma AG; serving on an advisory board for AstraZeneca; and serving on the advanced radiation therapy committee, International Association for the Study of Lung Cancer. Dawn Owen reports payment from UpToDate and receipt of goods/services from AstraZeneca and Varian Medical Systems. Marta Scorsetti reports grants or contracts from Varian Medical Systems, Sofar, and IPSEN. Jenniefer Y. Wo reports grants or contracts from Genentech. Maria Reig reports grants or contracts from Bayer, Ipsen, and ISCII; serving as a consultant or on advisory boards and/or receiving travel support from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, Geneos Therapeutics, UniveralDx, MSD and Lilly; receiving lecture fees from Bayer, BMS, Gilead, AstraZeneca, ROCHE and Lilly; receiving support for attending meetings and/or travel from Bayer, BMS, Roche, Ipsen, AstraZeneca, Eisai, MSD, and Lilly; and serving as EASL representative in UEG. Laura A. Dawson reports serving as chair of ASTRO., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
31. Tumor Response on Diagnostic Imaging after Proton Beam Therapy for Hepatocellular Carcinoma.
- Author
-
Niitsu H, Mizumoto M, Li Y, Nakamura M, Ishida T, Iizumi T, Saito T, Numajiri H, Makishima H, Nakai K, Oshiro Y, Maruo K, and Sakurai H
- Abstract
Background: Follow-up after treatment for hepatocellular carcinoma (HCC) can be mostly performed using dynamic CT or MRI, but there is no common evaluation method after radiation therapy. The purpose of this study is to examine factors involved in tumor reduction and local recurrence in patients with HCC treated with proton beam therapy (PBT) and to evaluate HCC shrinkage after PBT., Methods: Cases with only one irradiated lesion or those with two lesions irradiated simultaneously were included in this study. Pre- and post-treatment lesions were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) by measuring the largest diameter., Results: The 6-, 12-, and 24-month CR + PR rates after PBT were 33.1%, 57.5%, and 76.9%, respectively, and the reduction rates were 25.1% in the first 6 months, 23.3% at 6-12 months, and 14.5% at 13-24 months. Cases that reached CR/PR at 6 and 12 months had improved OS compared to non-CR/non-PR cases., Conclusions: It is possible that a lesion that reached SD may subsequently transition to PR; it is reasonable to monitor progress with periodic imaging evaluations even after 1 year of treatment.
- Published
- 2024
- Full Text
- View/download PDF
32. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
- Author
-
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, Kenyon M, Aljurf M, Bonfim C, Makishima H, Niemeyer C, Fenaux P, Zebisch A, Hamad N, Chalandon Y, Hellström-Lindberg E, Voso MT, Mecucci C, Duarte FB, Sebert M, Sicre de Fontbrune F, Soulier J, Shimamura A, Lindsley RC, Maciejewski JP, Calado RT, Yakoub-Agha I, and McLornan DP
- Subjects
- Humans, Transplantation, Homologous, Surveys and Questionnaires, Transplantation Conditioning methods, Disease Susceptibility, Hematopoietic Stem Cell Transplantation methods, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes therapy, Neoplasms, Graft vs Host Disease prevention & control
- Abstract
The recent application of whole exome or whole genome sequencing unveiled a plethora of germline variants predisposing to myeloid disorders, particularly myelodysplastic neoplasms. The presence of such variants in patients with myelodysplastic syndromes has important clinical repercussions for haematopoietic stem-cell transplantation, from donor selection and conditioning regimen to graft-versus-host disease prophylaxis and genetic counselling for relatives. No international guidelines exist to harmonise management approaches to this particular clinical scenario. Moreover, the application of germline testing, and how this informs clinical decisions, differs according to the expertise of individual clinical practices and according to different countries, health-care systems, and legislations. Leveraging the global span of the European Society for Blood and Marrow Transplantation (EBMT) network, we took a snapshot of the current European situation on these matters by disseminating an electronic survey to EBMT centres experienced in myelodysplastic syndromes transplantation. An international group of haematologists, transplantation physicians, paediatricians, nurses, and experts in molecular biology and constitutional genetics with experience in myelodysplastic syndromes contributed to this Position Paper. The panel met during multiple online meetings to discuss the results of the EBMT survey and to establish suggested harmonised guidelines for such clinical situations, which are presented here., Competing Interests: Declaration of interests YC has received consulting fees for advisory board from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, and Servier and travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz, and Sanofi all to his institution. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. Retrospective Analysis of the Areas Responsible for Light Flash and Odor During Proton Beam Therapy and Photon Therapy.
- Author
-
Oshiro Y, Mizumoto M, Miyamoto T, Sumiya T, Fujioka D, Shirataki H, Nakamura M, Ishida T, Iizumi T, Saito T, Numajiri H, Makishima H, Nakai K, Maruo K, Sakae T, and Sakurai H
- Abstract
Background Abnormal sensations were frequently experienced by patients who received irradiation of the brain or head and neck region. We have previously suggested correlations with irradiation of the nasal cavity and retina. Purpose We performed a retrospective dose-volume histogram analysis focused on the brain and head and neck tumor to examine the relationship between these abnormal sensations and the details of irradiation. Methods Multivariate logistic regression models were applied for the presence or absence of light flash and odor. Gender, age, radiotherapy method (proton beam therapy vs. photon radiotherapy), dose of retina, optic nerve, chiasmatic gland, pituitary, nasal cavity, oral cavity, frontal lobe, parietal lobe, occipital lobe, temporal lobe, amygdala, and hippocampus were set as candidates of explanatory variables. Results Light flash and odor during radiotherapy have been suggested to be associated with younger age and retina and nasal cavity irradiation. Multivariate analyses including dose-volume histograms indicated that light flash was related to age, chiasmatic gland irradiation, and pituitary dose, and odor was related to age and nasal cavity irradiation. Conclusion Our results indicate that light flash during radiotherapy is caused by irradiation of the visual pathway and that odor is caused by irradiation of the nasal cavity or olfactory bulb., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2023, Oshiro et al.)
- Published
- 2023
- Full Text
- View/download PDF
34. Proton beam therapy for hepatocellular carcinoma with bile duct invasion.
- Author
-
Iizumi T, Okumura T, Hasegawa N, Ishige K, Fukuda K, Seo E, Makishima H, Niitsu H, Takahashi M, Sekino Y, Takahashi H, Takizawa D, Oshiro Y, Baba K, Murakami M, Saito T, Numajiri H, Mizumoto M, Nakai K, and Sakurai H
- Subjects
- Aged, Humans, Bile Ducts, Progression-Free Survival, Middle Aged, Aged, 80 and over, Carcinoma, Hepatocellular, Liver Neoplasms, Proton Therapy adverse effects, Proton Therapy methods
- Abstract
Aim: Hepatocellular carcinoma (HCC) with bile duct invasion (BDI) (BDIHCC) has a poor prognosis. Moreover, due to the paucity of reports, there is no consensus regarding optimal management of this clinical condition yet. The aim of this study was to clarify the efficacy and safety of proton beam therapy (PBT) for BDIHCC., Methods: Between 2009 and 2018, 15 patients with BDIHCC underwent PBT at our institution. The overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. Toxicities were assessed using the Common Terminology Criteria of Adverse Events version 4.0., Results: The median follow-up time was 23.4 months (range, 7.9-54.3). The median age was 71 years (range, 58-90 years). Many patients were Child A (n = 8, 53.3%) and most had solitary tumors (n = 11, 73.3%). Additionally, most patients had central type BDI (n = 11, 73%). The median tumor size was 4.0 cm (range, 1.5-8.0 cm). The 1-, 2-, and 3-year OS rates were 80.0%, 58.7% and 40.2%, respectively, and the corresponding LC and PFS rates were 93.3%, 93.3%, and 74.7% and 72.7%, 9.7%, and 0.0%, respectively. Acute grade 1/2 dermatitis (n = 7, 46.7%), and grades 2 (n = 1, 6.7%) and 3 (n = 1, 6.7%) cholangitis were observed. Late toxicities such as grade 3 gastric hemorrhage and pleural effusion were observed. No toxicities of grade 4 or higher were observed., Conclusions: PBT was feasible with tolerable toxicities for the treatment of BDIHCC., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
35. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
- Author
-
Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, Creignou M, Zhao L, Kusakabe M, Shibata Y, Nakamura N, Watanabe M, Hiramoto N, Shiozawa Y, Shiraishi Y, Tanaka H, Yoshida K, Kakiuchi N, Makishima H, Nakagawa M, Usuki K, Watanabe M, Imada K, Handa H, Taguchi M, Kiguchi T, Ohyashiki K, Ishikawa T, Takaori-Kondo A, Tsurumi H, Kasahara S, Chiba S, Naoe T, Miyano S, Papaemanuil E, Miyazaki Y, Hellström-Lindberg E, and Ogawa S
- Subjects
- Humans, Prognosis, Treatment Outcome, Azacitidine, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics, Myeloproliferative Disorders, Neoplasms
- Abstract
Azacitidine is a mainstay of therapy for myelodysplastic syndrome (MDS)-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their posttreatment clone size. We enrolled a total of 449 patients with MDS or related myeloid neoplasms. They were analyzed for gene mutations in pretreatment (n = 449) and posttreatment (n = 289) bone marrow samples using targeted-capture sequencing to assess the impact of gene mutations and their posttreatment clone size on treatment outcomes. In Cox proportional hazard modeling, multihit TP53 mutation (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.42-2.91; P < .001), EZH2 mutation (HR, 1.71; 95% CI, 1.14-2.54; P = .009), and DDX41 mutation (HR, 0.33; 95% CI, 0.17-0.62; P < .001), together with age, high-risk karyotypes, low platelets, and high blast counts, independently predicted OS. Posttreatment clone size accounting for all drivers significantly correlated with International Working Group (IWG) response (P < .001, using trend test), except for that of DDX41-mutated clones, which did not predict IWG response. Combined, IWG response and posttreatment clone size further improved the prediction of the original model and even that of a recently proposed molecular prediction model, the molecular International Prognostic Scoring System (IPSS-M; c-index, 0.653 vs 0.688; P < .001, using likelihood ratio test). In conclusion, evaluation of posttreatment clone size, together with the pretreatment mutational profile as well as the IWG response play a role in better prognostication of azacitidine-treated patients with myelodysplasia., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
36. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
- Author
-
Mizumoto M, Terashima K, Makishima H, Suzuki M, Ogino T, Waki T, Iwata H, Tamamura H, Uchinami Y, Akimoto T, Okimoto T, Iizumi T, Murakami M, Katoh N, Maruo K, Shibuya K, and Sakurai H
- Abstract
Introduction: Intrahepatic cholangiocarcinoma (ICC) can be treated with chemotherapy in unresectable cases, but outcomes are poor. Proton beam therapy (PBT) may provide an alternative treatment and has good dose concentration that may improve local control., Methods: Fifty-nine patients who received initial PBT for ICC from May 2016 to June 2018 at nine centers were included in the study. The treatment protocol was based on the policy of the Japanese Society for Radiation Oncology. Forty patients received 72.6-76 Gy (RBE) in 20-22 fr, 13 received 74.0-76.0 Gy (RBE) in 37-38 fr, and 6 received 60-70.2 Gy (RBE) in 20-30 fr. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis., Results: The 59 patients (35 men, 24 women; median age: 71 years; range: 41-91 years) had PS of 0 ( n = 47), 1 ( n = 10), and 2 ( n = 2). Nine patients had hepatitis and all 59 cases were considered inoperable. The Child-Pugh class was A ( n = 46), B ( n = 7), and unknown ( n = 6); the median maximum tumor diameter was 5.0 cm (range 2.0-15.2 cm); and the clinical stage was I ( n = 12), II ( n = 19), III ( n = 10), and IV ( n = 18). At the last follow-up, 17 patients were alive (median follow-up: 36.7 months; range: 24.1-49.9 months) and 42 had died. The median OS was 21.7 months (95% CI: 14.8-34.4 months). At the last follow-up, 37 cases had recurrence, including 10 with local recurrence. The median PFS was 7.5 months (95% CI: 6.1-11.3 months). In multivariable analyses, Child-Pugh class was significantly associated with OS and PFS, and Child-Pugh class and hepatitis were significantly associated with local recurrence. Four patients (6.8%) had late adverse events of grade 3 or higher., Conclusion: PBT gives favorable treatment outcomes for unresectable ICC without distant metastasis and may be particularly effective in cases with large tumors., Competing Interests: The authors have no conflicts of interest to declare., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
37. Synchronization of light flash with the irradiation pulse in proton beam therapy: A case report.
- Author
-
Saito T, Mizumoto M, Oshiro Y, Miyamoto T, Kamizawa S, Nakamura M, Ishida T, Makishima H, Numajiri H, Nakai K, Sakae T, and Sakurai H
- Abstract
The correlation between sensory light flash and proton beam delivery was evaluated by measuring the timing of pulse beam delivery and light flash sensing using an event recorder in an 83-year-old patient receiving proton beam therapy (PBT) for nasopharyngeal adenoid cystic carcinoma. The treatment dose was 65 Gy (RBE) in 26 fractions with 2 ports, and both beams included the visual pathway (retina, optic nerve, chiasma). Measurements were obtained in 13 of the 26 fractions. The patient sensed a light flash in all 13 fractions and pressed the recorder button for 426 of the 430 pulsed beam deliveries, giving a sensing rate of 99.1%. The median duration of button-pressing of 0.3 s was almost the same as that of the beam pulse of 0.2 s, with a reaction time lag of 0.35 s. These results suggest a consistency between light flash during PBT and the timing of irradiation., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
38. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
- Author
-
Shimomura O, Endo M, Makishima H, Yamada T, Hashimoto S, Numajiri H, Miyazaki Y, Doi M, Furuya K, Takahashi K, Moriwaki T, Hasegawa N, Yamamoto Y, Niisato Y, Kobayashi M, Mizumoto M, Nakai K, Saito T, Hoshiai S, Saida T, Mathis BJ, Mori K, Nakajima T, Tsuchiya K, Sakurai H, and Oda T
- Subjects
- Humans, Albumins, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Gemcitabine, Paclitaxel therapeutic use, Protons, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal drug therapy, Hyperthermia, Induced, Pancreatic Neoplasms pathology
- Abstract
Background: Locally advanced pancreatic ductal adenocarcinoma (PDAC), accounting for about 30% of PDAC patients, is difficult to cure by radical resection or systemic chemotherapy alone. A multidisciplinary strategy is required and our TT-LAP trial aims to evaluate whether triple-modal treatment with proton beam therapy (PBT), hyperthermia, and gemcitabine plus nab-paclitaxel is a safe and synergistically effective treatment for patients with locally advanced PDAC., Methods: This trial is an interventional, open-label, non-randomized, single-center, single-arm phase I/II clinical trial organized and sponsored by the University of Tsukuba. Eligible patients who are diagnosed with locally advanced pancreatic cancer, including both borderline resectable (BR) and unresectable locally advanced (UR-LA) patients, and selected according to the inclusion and exclusion criteria will receive triple-modal treatment consisting of chemotherapy, hyperthermia, and proton beam radiation. Treatment induction will include 2 cycles of chemotherapy (gemcitabine plus nab-paclitaxel), proton beam therapy, and 6 total sessions of hyperthermia therapy. The initial 5 patients will move to phase II after adverse events are verified by a monitoring committee and safety is ensured. The primary endpoint is 2-year survival rate while secondary endpoints include adverse event rate, treatment completion rate, response rate, progression-free survival, overall survival, resection rate, pathologic response rate, and R0 (no pathologic cancer remnants) rate. The target sample size is set at 30 cases., Discussion: The TT-LAP trial is the first to evaluate the safety and effectiveness (phases1/2) of triple-modal treatment comprised of proton beam therapy, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer., Ethics and Dissemination: This protocol was approved by the Tsukuba University Clinical Research Review Board (reference number TCRB22-007). Results will be analyzed after study recruitment and follow-up are completed. Results will be presented at international meetings of interest in pancreatic cancer plus gastrointestinal, hepatobiliary, and pancreatic surgeries and published in peer-reviewed journals., Trial Registration: Japan Registry of Clinical Trials, jRCTs031220160. Registered 24 th June 2022, https://jrct.niph.go.jp/en-latest-detail/jRCTs031220160 ., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
39. Clinical impact of carbon-ion radiotherapy on hepatocellular carcinoma with Child-Pugh B cirrhosis.
- Author
-
Hiroshima Y, Wakatsuki M, Kaneko T, Makishima H, Okada NN, Yasuda S, Ishikawa H, and Tsuji H
- Subjects
- Humans, Retrospective Studies, Liver Cirrhosis complications, Recurrence, Carbon therapeutic use, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular radiotherapy, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms complications, Liver Neoplasms radiotherapy, Liver Neoplasms drug therapy
- Abstract
Background and Aims: Hepatocellular carcinoma (HCC) patients with Child-Pugh (CP)-B not eligible for surgery nor other focal therapy options due to impaired liver function, have very limited treatment options. This study aims to retrospectively investigate the toxicity and efficacy of Carbon-ion radiotherapy (C-ion RT) on HCC with CP-B patients., Materials and Methods: Patients with CP-B, no extrahepatic metastasis, and treated with C-ion RT between May 2000 and March 2020 were retrospectively extracted and included in this study., Results: Sixty-nine lesions of 58 patients were included. The median follow-up duration was 20.5 (2.7-108) months. During follow-up, recurrence was observed in 43 patients, including 2 local recurrences and 39 intrahepatic recurrences beyond the irradiation field. A grade 3 acute hepatotoxicity was observed in one patient during the observation period. No acute or late adverse event of grade ≥4 was observed. Overall survival was 80.4% and 46.0% at 1 and 2 years, respectively, and the median survival time was 22.6 months. Local control rate was 96.4% at both 1 and 2 years, and progression-free survival was 38.6% and 6.9% at 1 and 2 years, respectively, with a median of 9.7 months., Conclusion: The C-ion RT showed low toxicity and good local effect in patients with HCC and CP-B. Therefore, C-ion RT could be an appropriate treatment for patients with HCC with poor liver function., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
40. Analysis of person-hours required for proton beam therapy for pediatric tumors.
- Author
-
Mizumoto M, Fukushima H, Miyamoto T, Oshiro Y, Sumiya T, Iizumi T, Saito T, Makishima H, Numajiri H, Hosaka S, Nagatomo K, Yamaki Y, Nakai K, and Sakurai H
- Subjects
- Humans, Child, Hypnotics and Sedatives therapeutic use, Pediatrics methods, Child, Preschool, Proton Therapy, Health Personnel, Neoplasms radiotherapy, Time Management
- Abstract
Proton beam therapy (PBT) is effective for pediatric tumors, but patients may require sedation and other preparations, which extend the treatment time. Pediatric patients were classified into sedation and non-sedation cases. Adult patients were classified into three groups based on irradiation from two directions without or with respiratory synchronization and patch irradiation. Treatment person-hours were calculated as follows: (time from entering to leaving the treatment room) × (number of required personnel). A detailed analysis showed that the person-hours required for the treatment of pediatric patients are about 1.4-3.5 times greater than those required for adult patients. With the inclusion of additional time for the preparation of pediatric patients, PBT for pediatric cases is two to four times more labor-intensive than for typical adult cases., (© The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
41. DDX41-associated susceptibility to myeloid neoplasms.
- Author
-
Makishima H, Bowman TV, and Godley LA
- Subjects
- Animals, Female, Germ-Line Mutation, RNA, Messenger, Humans, Male, DEAD-box RNA Helicases genetics, Leukemia, Myeloid, Myeloproliferative Disorders genetics
- Abstract
Deleterious germ line DDX41 variants confer risk for myeloid neoplasms (MNs) and less frequently for lymphoid malignancies, with autosomal dominant inheritance and an estimated prevalence of 3% among MNs. Germ line DDX41 variants include truncating alleles that comprise about two-thirds of all alleles, missense variants located preferentially within the DEAD-box domain, and deletion variants. The identification of a truncating allele on tumor-based molecular profiling should prompt germ line genetic testing because >95% of such alleles are germ line. Somatic mutation of the wild-type DDX41 allele occurs in about half of MNs with germ line DDX41 alleles, typically in exons encoding the helicase domain and most frequently as R525H. Several aspects of deleterious germ line DDX41 alleles are noteworthy: (1) certain variants are common in particular populations, (2) MNs develop at older ages typical of de novo disease, challenging the paradigm that inherited cancer risk always causes disease in young people, (3) despite equal frequencies of these variants in men and women, men progress to MNs more frequently, suggesting a gender-specific effect on myeloid leukemogenesis, and (4) individuals with deleterious germ line DDX41 variants develop acute severe graft-versus-host disease after allogeneic hematopoietic cell transplantation with wild-type donors more than others unless they receive posttransplant cyclophosphamide, suggesting a proinflammatory milieu that stimulates donor-derived T cells. Biochemical studies and animal models have identified DDX41's ability to interact with double-stranded DNA and RNA:DNA hybrids with roles in messenger RNA splicing, ribosomal RNAs or small nucleolar RNAs processing, and modulation of innate immunity, disruption of which could promote inflammation and drive tumorigenesis., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
42. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
- Author
-
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, and Ogawa S
- Subjects
- Adult, Aged, 80 and over, Female, Humans, Male, Germ Cells, Mutation, DEAD-box RNA Helicases genetics, Leukemia, Myeloid, Acute genetics, Myelodysplastic Syndromes genetics, Myeloproliferative Disorders genetics
- Abstract
Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization of DDX41-mutated MNs, enrolling a total of 346 patients with DDX41 pathogenic/likely-pathogenic (P/LP) germ line variants and/or somatic mutations from 9082 MN patients, together with 525 first-degree relatives of DDX41-mutated and wild-type (WT) patients. P/LP DDX41 germ line variants explained ∼80% of known germ line predisposition to MNs in adults. These risk variants were 10-fold more enriched in Japanese MN cases (n = 4461) compared with the general population of Japan (n = 20 238). This enrichment of DDX41 risk alleles was much more prominent in male than female (20.7 vs 5.0). P/LP DDX41 variants conferred a large risk of developing MNs, which was negligible until 40 years of age but rapidly increased to 49% by 90 years of age. Patients with myelodysplastic syndromes (MDS) along with a DDX41-mutation rapidly progressed to acute myeloid leukemia (AML), which was however, confined to those having truncating variants. Comutation patterns at diagnosis and at progression to AML were substantially different between DDX41-mutated and WT cases, in which none of the comutations affected clinical outcomes. Even TP53 mutations made no exceptions and their dismal effect, including multihit allelic status, on survival was almost completely mitigated by the presence of DDX41 mutations. Finally, outcomes were not affected by the conventional risk stratifications including the revised/molecular International Prognostic Scoring System. Our findings establish that MDS with DDX41-mutation defines a unique subtype of MNs that is distinct from other MNs., (© 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
43. Estimation of post-therapeutic liver reserve capacity using 99m Tc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors.
- Author
-
Yamazaki K, Nishii R, Mizutani Y, Makishima H, Kaneko T, Isobe Y, Terada T, Tamura K, Imabayashi E, Tani T, Kobayashi M, Wakatsuki M, Tsuji H, and Higashi T
- Subjects
- Humans, Male, Carbon, Liver diagnostic imaging, Liver pathology, Radionuclide Imaging, Radiopharmaceuticals, Retrospective Studies, Technetium Tc 99m Aggregated Albumin, Technetium Tc 99m Pentetate, Female, Adult, Middle Aged, Aged, Aged, 80 and over, Hepatectomy methods, Liver Neoplasms diagnostic imaging, Liver Neoplasms radiotherapy, Liver Neoplasms pathology
- Abstract
Background: There is currently no established imaging method for assessing liver reserve capacity prior to carbon-ion radiotherapy (CIRT) for liver tumors. In order to perform safe CIRT, it is essential to estimate the post-therapeutic residual reserve capacity of the liver., Purpose: To evaluate the ability of pre-treatment
99m Tc-galactosyl human serum albumin (99m Tc-GSA) scintigraphy to accurately estimate the residual liver reserve capacity in patients treated with CIRT for liver tumors., Materials and Methods: This retrospective study evaluated patients who were performed CIRT for liver tumors between December 2018 and September 2020 and underwent99m Tc-GSA scintigraphy before and 3 months after CIRT, and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI within 1 month before CIRT were evaluated. The maximal removal rate of99m Tc-GSA (GSA-Rmax) was analyzed for the evaluation of pre-treatment liver reserve capacity. Then, the GSA-Rmax of the estimated residual liver (GSA-RL) was calculated using liver SPECT images fused with the Gd-EOB-DTPA-enhanced MRI. GSA-RL before CIRT and GSA-Rmax at 3 months after CIRT were compared using non-parametric Wilcoxon signed-rank test and linear regression analysis., Results: Overall, 50 patients were included (mean age ± standard deviation, 73 years ± 11; range, 29-89 years, 35 men). The median GSA-RL was 0.393 [range, 0.057-0.729] mg/min, and the median GSA-Rmax after CIRT was 0.369 [range, 0.037-0.780] mg/min (P = .40). The linear regression equation representing the relationship between the GSA-RL and GSA-Rmax after CIRT was y = 0.05 + 0.84x (R2 = 0.67, P < .0001). There was a linear relationship between the estimated and actual post-treatment values for all patients, as well as in the group with impaired liver reserve capacity (y = - 0.02 + 1.09x (R2 = 0.62, P = .0005))., Conclusions:99m Tc-GSA scintigraphy has potential clinical utility for estimating the residual liver reserve capacity in patients undergoing carbon-ion radiotherapy for liver tumors., Trial Registration: UMIN000038328, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000043545 ., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
44. [Radiotherapy for hepatocellular carcinomas].
- Author
-
Makishima H, Mizumoto M, and Sakurai H
- Subjects
- Humans, Carcinoma, Hepatocellular radiotherapy, Liver Neoplasms radiotherapy, Liver Neoplasms pathology
- Published
- 2023
- Full Text
- View/download PDF
45. Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma.
- Author
-
Fujita N, Kanogawa N, Makishima H, Ogasawara S, Maruta S, Iino Y, Shiko Y, Kanzaki H, Koroki K, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Nakamoto S, Chiba T, Wakatsuki M, Itobayashi E, Obu M, Koma Y, Azemoto R, Kawasaki Y, Kato J, Tsuji H, and Kato N
- Abstract
Aim: Carbon-ion radiotherapy (C-ion RT) has shown potential as a curative treatment for patients with hepatocellular carcinoma (HCC). However, no reports have compared the effectiveness of C-ion RT and radiofrequency ablation (RFA). This study aimed to compare clinical outcomes between C-ion RT and RFA for patients with early-stage HCC., Methods: Medical records of consecutive patients with HCC (single lesion ≤5 cm or two to three lesions ≤3 cm) who received either C-ion RT or RFA as initial treatment were retrospectively reviewed. Propensity score matching (PSM) was used to adjust for clinical factors between both groups., Results: A total of 560 patients were included, among whom 69 and 491 received C-ion RT and RFA, respectively. After PSM (C-ion RT, 54 patients; RFA, 95 patients), both groups were well balanced. Carbon-ion radiotherapy had significantly lower cumulative intrasubsegmental recurrence rate after PSM compared to RFA (p = 0.004) (2-year, 12.6% vs. 31.7%; 5-year, 15.5% vs. 49.6%, respectively). However, no significant difference in cumulative local recurrence rate, stage progression-free survival, or overall survival (OS) was observed between both groups. In the RFA group, 6 of 491 patients (1.2%) showed grade 3 adverse events, whereas no grade 3 or higher adverse events were observed in the C-ion RT group., Conclusion: Carbon-ion radiotherapy provided a lower cumulative intrasubsegmental recurrence rate, but a comparable cumulative local recurrence rate, stage progression-free survival, and OS compared to RFA. Thus, C-ion RT appears to be one of the effective treatment options for early-stage HCC when RFA is deemed not indicated., (© 2022 The Japan Society of Hepatology.)
- Published
- 2022
- Full Text
- View/download PDF
46. Factors Involved in Preoperative Edema in High-Grade Gliomas.
- Author
-
Saito T, Mizumoto M, Liang HK, Nakai K, Sumiya T, Iizumi T, Kohzuki H, Numajiri H, Makishima H, Tsurubuchi T, Matsuda M, Ishikawa E, and Sakurai H
- Abstract
Background Expansion of preoperative edema (PE) is an independent poor prognostic factor in high-grade gliomas. Evaluation of PE provides important information that can be readily obtained from magnetic resonance imaging (MRI), but there are few reports on factors associated with PE. The goal of this study was to identify factors contributing to PE in Grade 3 (G3) and Grade 4 (G4) gliomas. Methodology PE was measured in 141 pathologically proven G3 and G4 gliomas, and factors with a potential relationship with PE were examined in univariate and multivariate analyses. The following eight explanatory variables were used: age, sex, Karnofsky performance status (KPS), location of the glioma, tumor diameter, pathological grade, isocitrate dehydrogenase (IDH)-1-R132H status, and Ki-67 index. Overall survival (OS) and progression-free survival (PFS) were calculated in groups divided by PE (<1 vs. ≥1 cm) and by factors with a significant correlation with PE in multivariate analysis. Results In univariate analysis, age (p = 0.013), KPS (p = 0.012), pathology grade (p = 0.004), and IDH1-R132H status (p = 0.0003) were significantly correlated with PE. In multivariate analysis, only IDH1-R132H status showed a significant correlation (p = 0.036), with a regression coefficient of -0.42. The median follow-up period in survivors was 38.9 months (range: 1.2-131.7 months). The one-, two-, and three-year OS rates for PE <1 vs. ≥1 cm were 77% vs. 68%, 67% vs. 44%, and 63% vs. 24% (p = 0.0001), respectively, and those for IDH1-R132H mutated vs. wild-type cases were 85% vs. 67%, 85% vs. 40%, and 81% vs. 21% (p < 0.0001), respectively. The one-, two-, and three-year PFS rates for PE <1 vs. ≥1 cm were 77% vs. 49%, 64% vs. 24%, and 50% vs. 18% (p = 0.0002), respectively, and those for IDH1-R132H mutated vs. wild-type cases were 85% vs. 48%, 77% vs. 23%, and 73% vs. 14% (p < 0.0001), respectively. Conclusions IDH1-R132H status was found to be a significant contributor to PE. Cases with PE <1 cm and those with the IDH1-R132H mutation clearly had a better prognosis., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2022, Saito et al.)
- Published
- 2022
- Full Text
- View/download PDF
47. Abnormal sensation during total body irradiation: a prospective observational study.
- Author
-
Mizumoto M, Oshiro Y, Miyamoto T, Sumiya T, Shimizu S, Iizumi T, Saito T, Makishima H, Numajiri H, Nakai K, Okumura T, Sakae T, Maruo K, and Sakurai H
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Odorants, Plastics, Smell, Ozone, Whole-Body Irradiation adverse effects
- Abstract
Light flash and odor during radiotherapy are well-known phenomena. Two prospective observational studies have indicated that 55% of patients observed a light flash during irradiation of the retina and 27% of patients sensed an odor during radiotherapy for the nasal cavity. A prospective observational study was performed in all patients at our hospital who received total body irradiation (TBI) between January 2019 to October 2021. Light flash and odor during TBI were examined using the same method as that used in previous studies. A total of 32 patients received TBI during the study period. The patients had a median age of 41 (18-60) years, and included 20 males and 12 females. A survey checklist showed that 14 patients (44%) sensed light and 14 patients (44%) sensed odor during TBI,. The color of the light during irradiation was yellow in six cases, white in four cases, and blue in four cases. The intensity of the light was 2-5 (median 3, 1 is very weak, 5 is very strong) and the time over which the light flash was felt was 4-60 s (median 10 s). Two patients each sensed smells of plastic, ozone and bleach, and others sensed one smell each. The intensity of the odor was 1-4 (median 3, 1 is very weak, 5 is very strong) and the time over which the odor was sensed was 1-25 s (median 3 s). We conclude that light flashes and odors are each sensed by 44% of patients during TBI. Various types of light flashes and odors were reported in this study., (© The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.)
- Published
- 2022
- Full Text
- View/download PDF
48. Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia.
- Author
-
Takeda J, Yoshida K, Nakagawa MM, Nannya Y, Yoda A, Saiki R, Ochi Y, Zhao L, Okuda R, Qi X, Mori T, Kon A, Chiba K, Tanaka H, Shiraishi Y, Kuo MC, Kerr CM, Nagata Y, Morishita D, Hiramoto N, Hangaishi A, Nakazawa H, Ishiyama K, Miyano S, Chiba S, Miyazaki Y, Kitano T, Usuki K, Sezaki N, Tsurumi H, Miyawaki S, Maciejewski JP, Ishikawa T, Ohyashiki K, Ganser A, Heuser M, Thol F, Shih LY, Takaori-Kondo A, Makishima H, and Ogawa S
- Subjects
- Exome, Humans, Mutation, Prognosis, Janus Kinase 2 genetics, Leukemia, Erythroblastic, Acute drug therapy, Leukemia, Myeloid, Acute drug therapy, Receptors, Erythropoietin genetics
- Abstract
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, we analyzed 121 AEL using whole-genome, whole-exome, and/or targeted-capture sequencing, together with transcriptome analysis of 21 AEL samples. Combining publicly available sequencing data, we found a high frequency of gains and amplifications involving EPOR/JAK2 in TP53-mutated cases, particularly those having >80% erythroblasts designated as pure erythroid leukemia (10/13). These cases were frequently accompanied by gains and amplifications of ERG/ETS2 and associated with a very poor prognosis, even compared with other TP53-mutated AEL. In addition to activation of the STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism and often showed high sensitivity to ruxolitinib in vitro and in xenograft models, highlighting a potential role of JAK2 inhibition in therapeutics of AEL., Significance: This study reveals the major role of gains, amplifications, and mutations of EPOR and JAK2 in the pathogenesis of pure erythroleukemia. Their frequent response to ruxolitinib in patient-derived xenograft and cell culture models highlights a possible therapeutic role of JAK2 inhibition for erythroleukemia with EPOR/JAK2-involving lesions. This article is highlighted in the In This Issue feature, p. 369., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
49. The landscape of genetic aberrations in myxofibrosarcoma.
- Author
-
Takeuchi Y, Yoshida K, Halik A, Kunitz A, Suzuki H, Kakiuchi N, Shiozawa Y, Yokoyama A, Inoue Y, Hirano T, Yoshizato T, Aoki K, Fujii Y, Nannya Y, Makishima H, Pfitzner BM, Bullinger L, Hirata M, Jinnouchi K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Okamoto T, Haga H, Ogawa S, and Damm F
- Subjects
- Adult, DNA Copy Number Variations, Exome, Humans, Mutation, Neoplasm Recurrence, Local genetics, Exome Sequencing, Fibrosarcoma genetics, Sarcoma genetics, Soft Tissue Neoplasms genetics
- Abstract
Myxofibrosarcoma (MFS) is a rare subtype of sarcoma, whose genetic basis is poorly understood. We analyzed 69 MFS cases using whole-genome (WGS), whole-exome (WES) and/or targeted-sequencing (TS). Newly sequenced genomic data were combined with additional deposited 116 MFS samples. WGS identified a high number of structural variations (SVs) per tumor most frequently affecting the TP53 and RB1 loci, 40% of tumors showed a BRCAness-associated mutation signature, and evidence of chromothripsis was found in all cases. Most frequently mutated/copy number altered genes affected known disease drivers such as TP53 (56.2%), CDKN2A/B (29.7%), RB1 (27.0%), ATRX (19.5%) and HDLBP (18.9%). Several previously unappreciated genetic aberrations including MUC17, FLG and ZNF780A were identified in more than 20% of patients. Longitudinal analysis of paired diagnosis and relapse time points revealed a 1.2-fold mutation number increase accompanied with substantial changes in clonal composition over time. Our study highlights the genetic complexity underlying sarcomagenesis of MFS., (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2022
- Full Text
- View/download PDF
50. Light flash and odor during proton beam therapy for pediatric patients: a prospective observational study.
- Author
-
Mizumoto M, Oshiro Y, Miyamoto T, Sumiya T, Baba K, Murakami M, Shimizu S, Iizumi T, Saito T, Makishima H, Numajiri H, Nakai K, Okumura T, Maruo K, Sakae T, and Sakurai H
- Abstract
Light flash and odor during radiation therapy are well-known phenomena, but the details are poorly understood, particularly in pediatric patients. Therefore, we conducted a prospective observational study of these events in pediatric patients (age ≤20 years old) who received radiotherapy at our center from January 2019 to November 2021. Light flash and odor were evaluated using a patient-reported checklist including the presence, strength, and duration of the phenomenon, and color of light or type of odor. 53 patients who received proton therapy (n=47) and photon radiotherapy (n=6) were enrolled in this study. The median age of the patients was 10, ranged from 5 to 20. The patients who was able to see the light flash was 4, and all of them received retina irradiation. This was equivalent to 57% of the patients who received radiotherapy to retina (n=7). The light was bright and colored mainly blue and purple, which seemed to be consistent with Cherenkov light. Odor was sensed by 9 (17%) patients, and seven patients of the 9 received nasal cavity irradiation. This was equivalent to 41% of the patients who received nasal cavity irradiation (n=17). Other 2 patients received proton therapy to brain tumor. The odors were mainly described as plastic, burnt and disinfectant, which may be caused by ozone generated during irradiation. These data suggest that pediatric patients with retinal and nasal cavity irradiation frequently sense light flashes or odor. So adequate care is necessary so that these patients are not worried about this phenomenon., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Mizumoto, Oshiro, Miyamoto, Sumiya, Baba, Murakami, Shimizu, Iizumi, Saito, Makishima, Numajiri, Nakai, Okumura, Maruo, Sakae and Sakurai.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.